Combinature and InterMune collaborate on NMR fragment screening
Appreciating the scientific challenge, Dr. Markus Schade, VP of NMR Drug Discovery at Combinature, comments: "NMR screening is an ideal technique to screen medium size libraries for novel fragment binders which become the starting point for novel chemical matter with favourable ADME/Tox properties. The unique structural information on fragment binding sites allows for the immediate classification of hits and assists follow-up hit-to-lead chemistry. We are enthusiastic about providing InterMune with novel chemotypes for their drug discovery programs."
Most read news
Other news from the department business & finance
Get the analytics and lab tech industry in your inbox
From now on, don't miss a thing: Our newsletter for analytics and lab technology brings you up to date every Tuesday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.